Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer

  • Anti-CD39 monoclonal antibody IPH5201 advances to Phase 2 study in lung cancer
  • Innate to receive $5M milestone payment from AstraZeneca

https://finance.yahoo.com/news/innate-pharma-announces-iph5201-phase-050000097.html

RelatedNews

Signup today for free and be the first to get notified of breaking news.

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist